Wolfe Research upgraded Repligen (RGEN) to Outperform from Peer Perform with a $160 price target The firm sees a “great entry point” on the post-earnings selloff. Repligen reported a “solid” Q1 and is a top pure-play in bioprocessing, a sector that has “good houses” in a tough tools backdrop, the analyst tells investors in a research note. Repligen in afternoon trading is down 2% to $141.25. note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen’s Strong Q1 Performance and Strategic Positioning Earns ‘Buy’ Rating from Analyst
- Repligen’s Strong Q1 Performance and Strategic Acquisition Justify Buy Rating
- Repligen reports Q1 adjusted EPS 39c, consensus 35c
- Repligen sees FY25 adjusted EPS $1.63-$1.72, consensus $1.71
- Is RGEN a Buy, Before Earnings?